THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [12.32]-CMP175 ID: TIP-MED-000445 ⚠️ HIGH-ALERT / SPECIALIST SUPERVISION

Adrenaline (Epinephrine) Tartrate IP [Supplementary Emergency Module App-B.1]

Active Ingredient / Scientific Identity: Adrenaline • Class: Competitive Muscarinic Acetylcholine Receptor Antagonist (Anticholinergic Antidote & Vagolytic)

⚖️ Compare Profile
Generic / Entity NameAdrenaline (Epinephrine) Tartrate IP [Supplementary Emergency Module App-B.1] ([12.32]-CMP175)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassCompetitive Muscarinic Acetylcholine Receptor Antagonist (Anticholinergic Antidote & Vagol
Available Dosage FormsStandard approved strengths (refer to comparative context)
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o🚨 Clinically High-Alert: Independent Dose & Route Verification Required

1. Clinical & Scientific Overview

Adrenaline (Epinephrine) Tartrate IP [Supplementary Emergency Module App-B.1] (TIP-MED-000445, Reference Code [12.32]-CMP175) is classified under Vaccines, Immunologicals & Emergency Toxicology Antidotes (Ch 12) as a Competitive Muscarinic Acetylcholine Receptor Antagonist (Anticholinergic Antidote & Vagolytic). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). 1:1000 (0.3–0.5 mg IM anterolateral thigh) for anaphylaxis; 1:10,000 (1 mg [10 mL] IV push) for cardiac arrest.
Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). 1:1000 (0.3–0.5 mg IM anterolateral thigh) for anaphylaxis; 1:10,000 (1 mg [10 mL] IV push) for cardiac arrest.
Dosage Forms & Available Strengths:
Standard approved strengths (refer to comparative context)
Routes: Oral / Parenteral

3. Mechanism of Action & Pharmacodynamics

Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). 1:1000 (0.3–0.5 mg IM anterolateral thigh) for anaphylaxis; 1:10,000 (1 mg [10 mL] IV push) for cardiac arrest.

4. Therapeutic Indications & Evidence-Supported Uses

  • First-line life-saving antidote in organophosphate (OP) and carbamate insecticide poisoning
  • symptomatic sinus bradycardia / AV nodal block
  • pre-anaesthetic antisialagogue
  • coadministration with Neostigmine in neuromuscular reversal

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Co-indexed per approved Author Decision DEC-01 (Option 1A; preserved in IP_Supplementary_Emergency_Module_App_B_1.json [App-B.1]). 1:1000 (0.3–0.5 mg IM anterolateral thigh) for anaphylaxis; 1:10,000 (1 mg [10 mL] IV push) for cardiac arrest.

Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Comparative pharmacokinetic profile co-indexed under [12.32].
Metabolism & Biotransformation:
Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.
Elimination & Renal Adjustment:
Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.
Hepatic Impairment Considerations:
Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindications: No absolute contraindications in life-threatening bradycardia or OP poisoning. Routine use contraindicated in narrow-angle glaucoma, myasthenia gravis (unless reversing cholinergic crisis), paralytic ileus, pyloric stenosis. • Precautions: CRITICAL INDIAN OP POISONING PEARLS: (1) The endpoint of Atropine titration in OP poisoning is a DRY CHEST (absence of bronchorrhoea/wheeze) and adequate haemodynamics—NOT pupil dilation (mydriasis lags behind or may not occur if ocular exposure occurred); (2) Correct hypoxia BEFORE or alongside the first Atropine bolus if possible to reduce ventricular fibrillation risk, but never delay Atropine in drowning-in-secretions bronchorrhoea; (3) In heart transplant recipients (denervated heart), Atropine is ineffective or causes paradoxical AV block.

Key Clinical Precautions: Renal: No adjustment in emergency resuscitation/poisoning. • Hepatic: No adjustment in emergency resuscitation/poisoning.

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Dry mouth, blurred vision, photophobia, flushing, tachycardia, urinary retention, constipation.
  • Atropine toxicity/delirium ('blind as a bat, mad as a hatter, red as a beet, hot as a hare, dry as a bone'), hyperthermia, ventricular tachyarrhythmias, acute angle-closure glaucoma.
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Antihistamines / TCAs / Phenothiazines -> additive anticholinergic delirium; Potassium chloride wax-matrix tablets -> GI ulceration due to delayed transit

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [12.32].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: For 1% Atropine eye drops: blurring of near vision and pupil dilation last for 7–14 days.
    • Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
    • Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
    • Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / CDSCO Schedule H / BNF 90th Ed

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Injection: 0.6 mg/mL (1 mL ampoule); High-Strength OP Poisoning Vial: 1 mg/mL (30 mL / 100 mL vial); Ophthalmic Drops/Ointment: 1% w/v.

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.